Quest Diagnostics (DGX) Research

Forward Estimates

EPS Estimates

Current Qtr

$2.82

$2.75$2.91

vs $2.62+7.7%

14 analysts

Next Qtr

$2.80

$2.74$2.92

vs $2.60+7.8%

14 analysts

Current Yr

$10.77

$10.55$11.11

vs $9.85+9.3%

17 analysts

Next Yr

$11.67

$11.33$12.30

vs $10.77+8.4%

17 analysts

Revenue Estimates

Current Qtr

$2.97B

$2.94B$3.00B

vs $2.76B+7.7%

12 analysts

Next Qtr

$3.01B

$2.97B$3.06B

vs $2.82B+6.9%

12 analysts

Current Yr

$11.85B

$11.79B$11.92B

vs $11.04B+7.4%

16 analysts

Next Yr

$12.38B

$12.21B$12.61B

vs $11.85B+4.4%

16 analysts

SEC filings →

View all 10-K, 10-Q, and 8-K filings for DGX on EDGAR.

DGX filing events and research context
Filed	Item	Context
Feb 26, 2026	business	Quest Diagnostics (DGX) operates primarily in the Diagnostic Information Services (DIS) market, providing clinical testing and diagnostic insights to physicians, hospitals, and patients. The company processes hundreds of millions of test requisitions annually, leveraging a vast network of laboratories and patient service centers. Its secondary business, Diagnostic Solutions (DS), provides risk assessment services for insurers and healthcare IT solutions. The company’s financial performance is driven by requisition volume and revenue per requisition. Key growth strategies include strategic acquisitions—such as the 2024 purchase of LifeLabs and 2025 assets from Spectra Laboratories—and the "Invigorate" program, a multi-year initiative targeting 3% annual cost savings through automation, AI, and operational efficiencies to offset inflationary pressures and reimbursement headwinds. Financial analysts should monitor several critical risks and trends: * Reimbursement Pressures: Ongoing regulatory uncertainty, including potential Medicare Clinical Laboratory Fee Schedule (CLFS) reforms and the impact of the Protecting Access to Medicare Act (PAMA). * Payer Mix Shifts: A trend toward rising patient responsibility and capitated payment arrangements, which impact revenue predictability. * Market Consolidation: Increased competition from hospital-affiliated and physician-office laboratories, alongside industry-wide pricing transparency challenges. * Legislative Impact: Potential revenue headwinds from the One Big Beautiful Bill Act (OBBBA) and the expiration of enhanced Premium Tax Credits.
Feb 26, 2026	mda	Quest Diagnostics (DGX) reported strong financial performance for 2025, with total net revenues reaching $11.04 billion, an 11.8% increase over 2024. This growth was primarily driven by the Diagnostic Information Services (DIS) segment, which accounts for over 95% of consolidated revenue. DIS revenue rose 12.2%, bolstered by a 12.3% increase in test volume—largely attributed to recent acquisitions, including LifeLabs—and 5.3% organic growth. Conversely, the Diagnostic Solutions (DS) business saw a 3.3% revenue decline due to reduced demand for insurance risk assessment services. Operating income grew 15.6% to $1.56 billion, despite higher operating costs from wage inflation, supply expenses, and integration efforts. The company’s "Invigorate" program continues to target 3% annual cost savings to offset inflationary pressures. Capital allocation remains focused on growth and shareholder returns; the company invested $527 million in capital expenditures and returned capital through $452 million in share repurchases and $353 million in dividends. Management also initiated "Project Nova," a multi-year, $250–$310 million investment to modernize "Order to Cash" infrastructure. While the company faces ongoing legal and regulatory scrutiny, including class-action litigation and government investigations, it maintains sufficient liquidity through $1.3 billion in available credit facilities to support operations and future acquisitions.
Feb 26, 2026	risk_factors	Quest Diagnostics (DGX) faces significant headwinds driven by the evolving U.S. healthcare landscape, characterized by industry consolidation, the shift toward value-based reimbursement, and increased patient cost-sharing. The company operates in a highly fragmented, competitive market, contending with hospital-affiliated laboratories, physician-office labs, and emerging consumer-initiated testing providers. These competitors increasingly leverage advanced technologies, such as digital pathology and point-of-care testing, which threaten to internalize diagnostic services and reduce demand for commercial laboratory testing. Financial performance is heavily influenced by government and private payer policies. Regulatory risks include ongoing uncertainty regarding Medicare reimbursement rates under PAMA, as well as aggressive enforcement of billing compliance and anti-kickback laws. The company’s reliance on complex IT infrastructure—currently undergoing modernization via "Project Nova"—exposes it to significant operational and cybersecurity risks, including potential data breaches and the challenges of integrating artificial intelligence. Furthermore, DGX faces persistent inflationary pressures on labor and supply costs, which are difficult to offset given limited pricing power. With approximately $5.7 billion in debt, the company’s financial flexibility remains sensitive to interest rate fluctuations and credit rating volatility, while its growth strategy depends on successfully navigating complex acquisitions and regulatory hurdles in both domestic and international markets.

Filed

Item

Context

Feb 26, 2026

business

Quest Diagnostics (DGX) operates primarily in the Diagnostic Information Services (DIS) market, providing clinical testing and diagnostic insights to physicians, hospitals, and patients. The company processes hundreds of millions of test requisitions annually, leveraging a vast network of laboratories and patient service centers. Its secondary business, Diagnostic Solutions (DS), provides risk assessment services for insurers and healthcare IT solutions. The company’s financial performance is driven by requisition volume and revenue per requisition. Key growth strategies include strategic acquisitions—such as the 2024 purchase of LifeLabs and 2025 assets from Spectra Laboratories—and the "Invigorate" program, a multi-year initiative targeting 3% annual cost savings through automation, AI, and operational efficiencies to offset inflationary pressures and reimbursement headwinds. Financial analysts should monitor several critical risks and trends: * **Reimbursement Pressures:** Ongoing regulatory uncertainty, including potential Medicare Clinical Laboratory Fee Schedule (CLFS) reforms and the impact of the Protecting Access to Medicare Act (PAMA). * **Payer Mix Shifts:** A trend toward rising patient responsibility and capitated payment arrangements, which impact revenue predictability. * **Market Consolidation:** Increased competition from hospital-affiliated and physician-office laboratories, alongside industry-wide pricing transparency challenges. * **Legislative Impact:** Potential revenue headwinds from the One Big Beautiful Bill Act (OBBBA) and the expiration of enhanced Premium Tax Credits.

Feb 26, 2026

mda

Quest Diagnostics (DGX) reported strong financial performance for 2025, with total net revenues reaching $11.04 billion, an 11.8% increase over 2024. This growth was primarily driven by the Diagnostic Information Services (DIS) segment, which accounts for over 95% of consolidated revenue. DIS revenue rose 12.2%, bolstered by a 12.3% increase in test volume—largely attributed to recent acquisitions, including LifeLabs—and 5.3% organic growth. Conversely, the Diagnostic Solutions (DS) business saw a 3.3% revenue decline due to reduced demand for insurance risk assessment services. Operating income grew 15.6% to $1.56 billion, despite higher operating costs from wage inflation, supply expenses, and integration efforts. The company’s "Invigorate" program continues to target 3% annual cost savings to offset inflationary pressures. Capital allocation remains focused on growth and shareholder returns; the company invested $527 million in capital expenditures and returned capital through $452 million in share repurchases and $353 million in dividends. Management also initiated "Project Nova," a multi-year, $250–$310 million investment to modernize "Order to Cash" infrastructure. While the company faces ongoing legal and regulatory scrutiny, including class-action litigation and government investigations, it maintains sufficient liquidity through $1.3 billion in available credit facilities to support operations and future acquisitions.

Feb 26, 2026

risk_factors

Quest Diagnostics (DGX) faces significant headwinds driven by the evolving U.S. healthcare landscape, characterized by industry consolidation, the shift toward value-based reimbursement, and increased patient cost-sharing. The company operates in a highly fragmented, competitive market, contending with hospital-affiliated laboratories, physician-office labs, and emerging consumer-initiated testing providers. These competitors increasingly leverage advanced technologies, such as digital pathology and point-of-care testing, which threaten to internalize diagnostic services and reduce demand for commercial laboratory testing. Financial performance is heavily influenced by government and private payer policies. Regulatory risks include ongoing uncertainty regarding Medicare reimbursement rates under PAMA, as well as aggressive enforcement of billing compliance and anti-kickback laws. The company’s reliance on complex IT infrastructure—currently undergoing modernization via "Project Nova"—exposes it to significant operational and cybersecurity risks, including potential data breaches and the challenges of integrating artificial intelligence. Furthermore, DGX faces persistent inflationary pressures on labor and supply costs, which are difficult to offset given limited pricing power. With approximately $5.7 billion in debt, the company’s financial flexibility remains sensitive to interest rate fluctuations and credit rating volatility, while its growth strategy depends on successfully navigating complex acquisitions and regulatory hurdles in both domestic and international markets.

Forward Estimates

DGX filing events and research context

Keep researching DGX

Related tickers

Related explainers

Forward Estimates